<DOC>
	<DOCNO>NCT01264939</DOCNO>
	<brief_summary>The study global Phase III , multicenter , randomize , double-blind , placebo control , parallel-group study evaluate safety efficacy omalizumab administer subcutaneously add-on therapy treatment adolescent adult patient age 12-75 diagnose chronic idiopathic urticaria ( CIU ) remain symptomatic despite standard-dosed H1 antihistamine treatment ( include dose 4 time approve dose level ) , H2 blocker , and/or leukotriene receptor antagonist ( LTRA ) .</brief_summary>
	<brief_title>A Safety Study Xolair ( Omalizumab ) Patients With Chronic Idiopathic Urticaria ( CIU ) Who Remain Symptomatic Despite Treatment With H1 Antihistamines , H2 Blockers , and/or Leukotriene Receptor Antagonists</brief_title>
	<detailed_description />
	<mesh_term>Urticaria</mesh_term>
	<mesh_term>Leukotriene Antagonists</mesh_term>
	<mesh_term>Omalizumab</mesh_term>
	<mesh_term>Diphenhydramine</mesh_term>
	<mesh_term>Promethazine</mesh_term>
	<mesh_term>Histamine H1 Antagonists</mesh_term>
	<mesh_term>Histamine Antagonists</mesh_term>
	<mesh_term>Histamine H2 Antagonists</mesh_term>
	<criteria>Diagnosis chronic idiopathic urticaria ( CIU ) refractory H1 antihistamine , H2 blocker , and/or leukotriene receptor antagonist ( LTRA ) time randomization . The presence itch hive &gt; 6 consecutive week time prior enrollment despite current use H1 antihistamine ( 4 time approved dosage ) , H2 blocker , and/or LTRA treatment time . Urticaria activity score 7 day ( UAS7 ) score ( range 0−42 ) ≥ 16 itch component UAS7 ( range 0−21 ) ≥ 8 7 day prior randomization ( Week 0 ) . Inclinic UAS ≥ 4 least one screen visit day ( Day −14 , Day −7 , Day 1 ) . For woman childbearing potential , agreement use acceptable form contraception continue use duration study . Treatment investigational agent within 30 day prior screen . Weight le 20 kg ( 44 lb ) . Clearly define underlying etiology chronic urticarias CIU . Evidence parasitic infection . Atopic dermatitis , bullous pemphigoid , dermatitis herpetiformis , senile pruritus , skin disease associate itch . Previous treatment omalizumab within year prior screen . Routine dos follow medication within 30 day prior screen : Systemic cutaneous ( topical ) corticosteroid ( prescription counter ) , hydroxychloroquine , methotrexate , cyclosporine , cyclophosphamide . Intravenous ( IV ) immunoglobulin G ( IVIG ) , plasmapheresis within 30 day prior screen . Regular ( daily/every day ) doxepin ( oral ) use within 6 week prior screen . Patients current malignancy , history malignancy , currently workup suspect malignancy except nonmelanoma skin cancer treat excise consider resolve . Hypersensitivity omalizumab component formulation . History anaphylactic shock . Presence clinically significant cardiovascular , neurological , psychiatric , metabolic , pathological condition could interfere interpretation study result compromise safety patient . Evidence current drug alcohol abuse .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2013</verification_date>
</DOC>